ARTRYA Ltd (AU:AYA) — Market Cap & Net Worth
Market Cap & Net Worth: ARTRYA Ltd (AYA)
ARTRYA Ltd (AU:AYA) has a market capitalization of $527.09 Million (AU$744.94 Million) as of June 17, 2026. Listed on the AU stock exchange, this Australia-based company holds position #12157 globally and #312 in its home market, demonstrating a -2.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ARTRYA Ltd's stock price AU$4.65 by its total outstanding shares 160202826 (160.20 Million). Review AYA liabilities breakdown to assess the company's total debt and financial obligations.
ARTRYA Ltd Market Cap History: 2021 to 2026
ARTRYA Ltd's market capitalization history from 2021 to 2026. Data shows growth from $147.93 Million to $527.09 Million (27.72% CAGR).
ARTRYA Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ARTRYA Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
19067.71x
ARTRYA Ltd's market cap is 19067.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $533.90 Million | $28.00K | -$16.41 Million | 19067.71x | N/A |
Competitor Companies of AYA by Market Capitalization
Companies near ARTRYA Ltd in the global market cap rankings as of June 17, 2026.
Key companies related to ARTRYA Ltd by market ranking:
- Veeva Systems Inc Class A (NYSE:VEEV): Ranked #1017 globally with a market cap of $26.54 Billion USD.
- Pro Medicus Ltd (AU:PME): Ranked #1955 globally with a market cap of $12.13 Billion USD ( AU$17.14 Billion AUD).
- BrightSpring Health Services, Inc. Common Stock (NASDAQ:BTSG): Ranked #2173 globally with a market cap of $10.63 Billion USD.
- Tempus AI, Inc. Class A Common Stock (NASDAQ:TEM): Ranked #2489 globally with a market cap of $8.78 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #1017 | Veeva Systems Inc Class A | NYSE:VEEV | $26.54 Billion | $163.38 |
| #1955 | Pro Medicus Ltd | AU:PME | $12.13 Billion | AU$164.11 |
| #2173 | BrightSpring Health Services, Inc. Common Stock | NASDAQ:BTSG | $10.63 Billion | $64.14 |
| #2489 | Tempus AI, Inc. Class A Common Stock | NASDAQ:TEM | $8.78 Billion | $50.56 |
ARTRYA Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, ARTRYA Ltd's market cap moved from $147.93 Million to $ 527.09 Million, with a yearly change of 27.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$527.09 Million | -1.27% |
| 2025 | AU$533.90 Million | +788.68% |
| 2024 | AU$60.08 Million | +120.83% |
| 2023 | AU$27.20 Million | -40.00% |
| 2022 | AU$45.34 Million | -69.35% |
| 2021 | AU$147.93 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of ARTRYA Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $527.09 Million USD |
| MoneyControl | $527.09 Million USD |
| MarketWatch | $527.09 Million USD |
| marketcap.company | $527.09 Million USD |
| Reuters | $527.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ARTRYA Ltd
Artrya Limited, a medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. The company offers Salix, a suite ifcloud-based software that uses artificial intelligence to automate the detection of coronary artery disease from coronary computed tomography angiography sca… Read more